$GH

Hidalgo Medina Manuel sold $130K of GH

Hidalgo Medina Manuel sold 1,000 shares of Guardant Health, Inc. (GH) at $130.06 ($0.13M total) on 2026-05-28.

Original reporting
SEC EDGAR · Hidalgo Medina Manuel
Published May 29, 2026, 9:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI May 29, 2026, 9:34 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$GH
Neutral
medium confidence
Mentioned
$GH
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$GHNeutralLow
01

Why it matters

The disclosure updates insider-trading visibility but does not provide new company performance, guidance, or deal information.

02

Market read

Traders may monitor GH for any follow-on insider activity, but the filing alone is unlikely to drive a major repricing.

03

What to watch

No 10b5-1 plan is cited; traders may want to check prior Form 4 cadence and whether sales cluster around specific events or option exercises.

Relevance 6/10Novelty 6/10Timing: Filed after-hours/late day (2026-05-29T17:30:38-04:00) following the 2026-05-28 sale.

Background

The article is an SEC Form 4 disclosure reporting an insider (director) transaction in Guardant Health shares.

Company-level read

Ticker impact

$GHNeutralMedium confidence
Context

Guardant Health director Hidalgo Medina Manuel filed a Form 4 open-market sale of 1,000 shares at ~$130.06 on 2026-05-28.

Expected impact

Low near-term impact; any reaction is likely limited unless part of a broader selling pattern.

Evidence & confidence

The filing is a director open-market sale with no 10b5-1 plan stated and no accompanying company-specific operational news.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide development.

None indicated.

None indicated.

Counterpoint

A single director open-market sale may reflect diversification or routine liquidity needs rather than negative fundamentals.

Key entities

  • Guardant Health, Inc.

    Publicly traded company whose director filed the Form 4 insider sale.

  • Hidalgo Medina Manuel

    Director who sold 1,000 GH shares at ~$130.06/share.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$GHHigh

Guardant Health (GH) Wins a New Breast Cancer Role. Can Its Growth Justify the Price?

Guardant Health (GH) received FDA approval for its Guardant360 CDx test as a companion diagnostic for AstraZeneca's camizestrant in advanced breast cancer. The company reported Q2 2026 revenue growth of 44% to $335 million, with oncology revenue up 38% and screening revenue up significantly. Despite strong revenue growth, the company reported an adjusted EBITDA loss of $55.9 million and negative free cash flow.

$GHMed

Guardant360 CDx Receives European Approval as Companion Diagnostic for Camizestrant in ESR1-Mutated Advanced Breast Cancer

Guardant360 CDx received EU approval as a companion diagnostic for AstraZeneca's camizestrant in ER-positive, HER2-negative advanced breast cancer. The blood test detects ESR1 mutations, aiding treatment decisions. The approval follows similar nods in the US and Japan, based on the SERENA-6 trial showing improved progression-free survival with camizestrant.